0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD200

CD200

CD200 Molecule Information

Name:OX-2 membrane glycoprotein
Target Synonym:My033?CD200?CD200 Antigen?Antigen Identified By Monoclonal Antibody MRC OX-2?MOX1?OX-2 Membrane Glycoprotein?OX-2?MRC?CD200 Molecule?MOX2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

CD200 Protein Product ListCompare or Buy

CD200 Part of Bioactivity data

OX2-H82F1-ELISA
Biotinylated Human CD200, Fc,AvitagBiotinylated Human CD200, Fc,Avitag (Cat. No. OX2-H82F1) ELISA bioactivity

Immobilized Human CD200 R1, His Tag (Cat. No. CR2-H52H6) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD200, Fc,Avitag (Cat. No. OX2-H82F1) with a linear range of 0.2-2 ng/mL (QC tested).

OX2-H82F7-ELISA
Biotinylated Human CD200, Fc (L234A, L235A, P329G),AvitagBiotinylated Human CD200, Fc (L234A, L235A, P329G),Avitag (Cat. No. OX2-H82F7) ELISA bioactivity

Immobilized Human CD200 R1, His Tag (Cat. No. CR2-H52H6) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD200, Fc (L234A, L235A, P329G),Avitag (Cat. No. OX2-H82F7) with a linear range of 0.2-1 ng/mL (QC tested).

CD200 Molecule Synonym Name

CD200,MOX1,MOX2,MRC,OX-2,My033

CD200 Molecule Background

CD200 is also known as OX-2 membrane glycoprotein (OX-2), is a type-1 membrane glycoprotein, which contains two immunoglobulin domains (1 Ig-like C2-type (immunoglobulin-like) domain and Ig-like V-type (immunoglobulin-like) domain), and thus belongs to the immunoglobulin superfamily. CD200 / OX-2 is widely expressed in multiple cell types. CD200 interacts with a structurally related receptor (CD200R) expressed mainly on myeloid cells and is involved in regulation of macrophage and mast cell function. OX-2 / CD200 and CD200R associate via their respective N-terminal Ig-like domains. CD200 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.

CD200 References

CD200 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Samalizumab ALXN-6000 Phase 2 Clinical Alexion Pharmaceuticals Inc, The Leukemia & Lymphoma Society Solid tumours; Multiple Myeloma; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell Details

This web search service is supported by Google Inc.

totop